For long-term users of combined oral contraceptives (COC), short-term hormonal withdrawal that occurs during the once-a-month pill pause appears to be accompanied by a significant increase in negative affect, anxiety, and mental health symptoms, regardless of COC type, as reported in a study.
Estimated glomerular filtration rate (eGFR) below age-expected values appears to indicate an increased risk for major adverse cardiovascular events (MACE) and MACE plus heart failure (MACE+) in young adults, according to a study.
Individuals with type 2 diabetes (T2D) who regularly consume ultraprocessed foods (UPF), regardless of diet quality, appear to have reduced survival and increased cardiovascular disease (CVD) mortality rate, suggests a recent study.
The Erection Hardness Scale (EHS) proves to be reliable in differentiating between predominantly organic and apparently nonorganic erectile dysfunction (ED), reducing the need for further nocturnal penile tumescence and rigidity (NPTR) testing, as reported in a study.
Coronary artery disease (CAD) stands as the foremost cause of mortality worldwide. In 2012, CAD accounted for 98.9 deaths per 100,000 people in Malaysia. Chronic stable angina is a common manifestation of CAD. The presence of chronic angina significantly increases the risk of major cardiovascular (CV) events, reduces quality of life (QoL) and adversely affects activities of daily living. Patients with this condition often present with several comorbidities, including hypertension, diabetes mellitus (DM),dyslipidaemia, atrial fibrillation (AF) and heart failure, further complicating the treatment approach.
Novugen is an innovator in the generics and biosimilars market. Since its inception, it has dived in headfirst into the industry, taking on difficulties and sparking new ideas. In this exclusive interview, Novugen’s CEO Rahil Mahmood explores the strategic moves that has set the stage to launching this Malaysian jewel to the forefront of the pharmaceutical world.
Dato’ Sri Dr Azhari Rosman, Senior Consultant Cardiologist at National Heart Institute, discusses the formidable situation of hypercholesterolaemia in Malaysia while Professor Dr Peter Jan Lansberg, Lipidologist at University Medical Center Groningen, The Netherlands, puts forth the solution of prescribing the highest tolerated dose of statins like atorvastatin calcium to treat patients to target low-density lipoprotein cholesterol (LDL-C) levels.
Heart failure (HF) is a global health problem, affecting over 26 million people worldwide. In Malaysia, HF is a common cause of hospitalization, accounting for approximately 6–10% of all acute medical admissions. It is also a prevalent reason for hospital readmissions. Between the years 2007 and 2016 in Malaysia, 18% of patients were readmitted within 30 days after discharge following an index hospitalisation for HF. Notably, the in-hospital, 30-day and 1-year mortality rates were 5.3%, 11.2% and 33.1%, respectively.
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in significant weight loss in patients with obesity or overweight without diabetes, a study has shown. In addition, the best GLP-1RA agent appears to be semaglutide, showing superior efficacy and low-to-moderate risk of side effects.